Centrient showcases its sustainability approach and European manufacturing resilience during visit from Dutch Deputy Prime Minister and Minister of Climate Policy and Green Growth, Sophie Hermans
- Centrient joins Alpbach Communiqué initiative to support European manufacturing
- Invests EUR 25 million to strengthen and modernize its Delft, Netherlands site
------------------------------------------------------------------------------------------
Delft, the Netherlands, February 2, 2026 – Centrient Pharmaceuticals,* a global leader in sustainable, enzymatic antibiotics, next‑generation statins, and anti‑fungals, today highlighted its progress in environmentally responsible pharmaceutical manufacturing and its commitment to a strong European medicines supply chain during a visit from Sophie Hermans, Dutch Deputy Prime Minister and Minister of Climate Policy and Green Growth.
The discussions focused on Centrient’s leadership in environmentally responsible production methods, including its pioneering use of enzymatic processes and its industry‑first achievement of full Predicted No-Effect Concentration (PNEC) compliance across all sites to ensure no harmful antibiotic residues enter the environment. Centrient leaders also outlined how sustainability initiatives, continuous innovation, and long‑term site investments support both Dutch industrial strength and Europe’s strategic autonomy in essential medicine manufacturing.
Minister Hermans visited Centrient’s flagship Delft site - one of the last remaining large‑scale antibiotic production facilities in Europe. The site produces around 50% of the world’s intermediates for widely used first‑generation cephalosporin antibiotics. These medicines are critical for global healthcare, supporting everything from childhood infections to routine and lifesaving surgeries.
During the visit, Centrient leaders outlined how the Delft site combines biotechnology innovation and industrial heritage, and explained a multi‑year investment programme to reduce its environmental footprint, strengthen its operational resilience, and ensure continued access to high‑quality, reliably produced antibiotics.
Alexander Krujatz, Chief Commercial Officer of Centrient Pharmaceuticals, said:
“Sustainability is not separate from supply resilience — it is an essential enabler of it. We were honoured to welcome Minister Hermans to Delft to demonstrate how our manufacturing capabilities support Europe’s long‑term access to essential medicines. Our ongoing investments in the Netherlands reflect both our commitment to sustainability and our determination to ensure that foundational antibiotics continue to be produced in Europe, responsibly and at scale.”
Centrient earlier this month announced that it has joined the European Forum Alpbach initiative on antibiotics, supporting the Alpbach Communiqué on the Manufacturing of Antibiotic Active Pharmaceutical Ingredients (API). Building on this role, Centrient will support the objectives of the Alpbach Communiqué, which calls for strengthened European resilience in antibiotic API manufacturing and reduced dependency on fragile global supply chains.
EUR 25 million upgrade reinforces Delft’s reliability and sustainability
The visit comes as Centrient progresses a EUR 25 million upgrade to strengthen and modernise the Delft facility. The project includes the installation of two new large steam generators and integration of upgraded process equipment, improving both energy efficiency and long‑term operational reliability.
These investments also pave the way for further enhancements, including a modernisation of the site’s wastewater treatment plant, ensuring that the Delft facility remains among the leading sites globally for sustainable antibiotic manufacturing.
A backbone of global healthcare
Centrient’s Delft plant is the largest and principal cephalosporin intermediate manufacturing site outside China. Medicines made using intermediates from Delft enable an estimated 1.5 billion treatments each year.
Future‑ready and purpose‑driven
Centrient is working closely with European stakeholders and global partners to ensure essential antibiotics continue to be produced sustainably and securely in Europe. These efforts also support the global fight against antimicrobial resistance (AMR) by advancing cleaner production technologies and strengthening environmental responsibility across the pharmaceutical supply chain.
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business‑to‑business leader in sustainable, enzymatic antibiotics, next‑generation statins, and anti‑fungals. We manufacture intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms (FDFs), improving lives through innovative and sustainable manufacturing of medicines used in millions of treatments worldwide.
For more information, visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse at neil.moorhouse@centrient.com.
*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.